3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Melanoma
23
Neoplasm Metastasis
11
Leukemia, Myeloid, Acute
11
Pancreatic Neoplasms
7
Ovarian Neoplasms
7
Carcinoma, Renal Cell
7
Leukemia
6
Kidney Neoplasms
6
Breast Neoplasms
6
Uterine Cervical Neoplasms
5
Stomach Neoplasms
5
Lymphoma
5
Carcinoma, Non-Small-Cell Lung
5
Neuroblastoma
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Colonic Neoplasms
4
Rectal Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasms
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Mantle-Cell
3
Lymphoma, Follicular
3
Leukemia, Myelomonocytic, Chronic
3
Gastrointestinal Neoplasms
3
Congenital Abnormalities
3
Vulvar Neoplasms
2
Vaginal Neoplasms
2
Uveal Melanoma
2
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Interventions
fludarabine
1
aldesleukin
1
Interleukin-2
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Ovarian Cancer Metastatic
×
aldesleukin
×
Clear all
NCT04389229
2020-12-16
OVSTAR
Immetacyte Ltd
Phase 1/2
Withdrawn